Document is current
Any future updates will be listed below
-
Authors
Chen, Kai https://orcid.org/0000-0002-3325-3536
Han, Hesong
Zhao, Sheng https://orcid.org/0009-0002-9890-048X
Xu, Bryant https://orcid.org/0009-0000-2464-6111
Yin, Boyan
Lawanprasert, Atip https://orcid.org/0009-0001-3163-8803
Trinidad, Marena
Burgstone, Benjamin W. https://orcid.org/0009-0000-8256-3867
Murthy, Niren https://orcid.org/0000-0002-7815-7337
Doudna, Jennifer A. https://orcid.org/0000-0001-9161-999X
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute
U.S. Department of Health & Human Services | National Institutes of Health (RM1HG009490, R01MH125979-01)
Life Sciences Research Foundation
Cystic Fibrosis Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (UM1AI164559)
California Institute for Regenerative Medicine (DISC2-14045, DISC2-14097)
- License Information
-
More Information
Article History
Received: 23 October 2023
Accepted: 18 September 2024
First Online: 16 October 2024
Competing interests
: The Regents of the University of California have patents issued and pending for CRISPR technologies on which K.C., H.H., S.Z., N.M. and J.A.D. are inventors. J.A.D. is a cofounder of Azalea Therapeutics, Caribou Biosciences, Editas Medicine, Evercrisp, Scribe Therapeutics, Intellia Therapeutics and Mammoth Biosciences. J.A.D. is a scientific advisory board member at Evercrisp, Caribou Biosciences, Intellia Therapeutics, Scribe Therapeutics, Mammoth Biosciences, The Column Group and Inari. J.A.D. is also an advisor for Aditum Bio. J.A.D. is chief science advisor to Sixth Street, is a director at Altos, Johnson & Johnson and Tempus and has research projects sponsored by Apple Tree Partners. N.M. and H.H. are founders of Opus Biosciences. The other authors declare no competing interests.
